ABSTRACT
Importance There is limited population-based evidence on the prevalence of cognitive impairment in Mexico, a country with a rapidly aging population and where key risk factors, such as diabetes and obesity, are common.
Objective To describe the distribution of cognitive impairment in a sample of adults from Mexico City.
Design, Setting, and Participants This cross-sectional population-based study included participants from the Mexico City Prospective Study which 50,000 men and 100,000 women aged ≥35 years from two districts in 1998-2004. In 2015-2019 about 10,000 survivors were resurveyed with identical information from the original survey and additional assessments including a cognitive assessment. The main analyses included those aged 50-89 years with complete cognitive assessment and covariate data at resurvey.
Main outcomes and measures Cognition was assessed using the Mini Mental State Examination (MMSE) and those with cognitive impairment (MMSE ≤24) were identified. The distribution of MMSE scores and cognitive impairment by age, sex, and major disease risk factors (diabetes, hypertension, and adiposity) was analyzed among those with complete MMSE data and some degree of self-reported formal education.
Results Of the 9,288 participants aged 50-89 years at the 2015-2019 resurvey with complete data, 8,197 reported having at least some years of formal education. Among these (mean age 66 years; 31% men), their mean MMSE score was 26.2 (SD 3.6) points, 1,941 (24%) had cognitive impairment, mean body-mass index (BMI) was 28.6 (SD 5.5) kg/m2, 3,008 (37%) had previously-diagnosed hypertension and 2,467 (30%) had previously-diagnosed diabetes. The sex- and district-standardised prevalence of cognitive impairment increased strongly with age, from 10% in those 50-59 years to 55% in those aged 80-89. At any given age, the prevalence of cognitive impairment was higher in women than in men. After accounting for the effects of age, sex, and district there was little difference in the prevalence of cognitive impairment between participants with or without diabetes, hypertension, overweight or obesity (BMI ≥25 km/m2), or high levels of fat mass.
Conclusion and relevance In this population of adults aged 50-89 years from two districts of Mexico City, the prevalence of cognitive impairment was high, particularly among women. The extent to which cognitive impairment relates to health outcomes in this population needs to be investigated.
Question What is the distribution of cognitive impairment among adults in Mexico City?
Findings In this cross-sectional study of 8,197 adults aged 50-89 years, the sex- and district-standardised prevalence of cognitive impairment ranged from 10% in those 50-59 years to 55% in those aged 80-89 and at any given age was higher in women than in men. There was little difference in the prevalence of cognitive impairment between participants with or without hypertension, diabetes or excess of adiposity.
Meaning Cognitive impairment is common in adults in Mexico City. Its relevance to major morbidity and mortality deserves future research.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Mexico City Prospective Study has received funding from the Mexican Health Ministry, the National Council of Science and Technology for Mexico, the Wellcome Trust (058299/Z/99), Cancer Research UK, the British Heart Foundation (RE/13/1/30181), and the UK Medical Research Council (MC_UU_00017/2).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Oxford, Oxford Tropical Research Ethics Committee, Granted 01 May 2014, Universidad Nacional Autónoma de México, Comité De ética De La Investigación, Granted 10 June 2020.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The Mexico City Prospective Study reflects a long-standing collaboration between researchers at the National Autonomous University of Mexico and the University of Oxford. Data from the Mexico City Prospective Study are available to bona fide researchers. The study's Data and Sample Sharing policy can be downloaded (in English or Spanish: https://www.ctsu.ox.ac.uk/research/mcps). Available study data can be examined in detail through the study's Data Showcase. (https://datashare.ndph.ox.ac.uk/mexico/)
